Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry

Proteomics

Volumn 12, Issue 8, 2012, Pages 1253-1260

  Schoenherr, Regine M ^a   Whiteaker, Jeffrey R ^a   Zhao, Lei ^a   Ivey, Richard G ^a   Trute, Mary ^a   Kennedy, Jacob ^a   Voytovich, Uliana J ^a   Yan, Ping ^a   Lin, Chenwei ^a   Paulovich, Amanda G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Estrogen receptor; HER2 Neu; Immunoaffinity; Peptides; Technology; Tissue

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PEPTIDE;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; BREAST CANCER; HUMAN; HUMAN CELL; IMMUNO SELECTED REACTION MONITORING ASSAY; IMMUNOASSAY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CALIBRATION; CELL EXTRACTS; CELL LINE; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860849265     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100587     Document Type: Article

References (51)

1. Gown, A. M., Current issues in ER and HER2 testing by IHC in breast cancer. Mod. Pathol. 2008, 21, S8-S15.
2. Harris, L., Fritsche, H., Mennel, R., Norton, L. et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287-5312.
3. Goldman, J. M., Melo, J. V., Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 2003, 349, 1451-1464.
4. Dorfman, D. M., Bui, M. M., Tubbs, R. R., Hsi, E. D. et al., The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study. Arch. Pathol. Lab. Med. 2006, 130, 779-782.
5. Paik, S., Bryant, J., Tan-Chiu, E., Romond, E. et al., Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 2002, 94, 852-854.
6. Saltz, L. B., Meropol, N. J., Loehrer, P. J., Sr., Needle, M. N. et al., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
7. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S. et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
8. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S. et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
9. Pao, W., Miller, V., Zakowski, M., Doherty, J. et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13306-13311.
10. Oien, K. A., Evans, T. R., Raising the profile of cancer of unknown primary. J. Clin. Oncol. 2008, 26, 4373-4375.
11. Papadopoulos, N., Kinzler, K. W., Vogelstein, B., The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol. 2006, 24, 985-995.
12. Yaziji, H., Taylor, C. R., Goldstein, N. S., Dabbs, D. J. et al., Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 2008, 16, 513-520.
13. Sauter, G., Lee, J., Bartlett, J. M., Slamon, D. J. et al., Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 2009, 27, 1323-1333.
14. Badve, S. S., Baehner, F. L., Gray, R. P., Childs, B. H. et al., Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J. Clin. Oncol. 2008, 26, 2473-2481.
15. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
16. Fu, Q., Schoenhoff, F. S., Savage, W. J., Zhang, P. et al., Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin. Appl. 2010, 4, 271-284.
17. Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L. et al., A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29, 625-634.
18. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R. et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 2011, 29, 635-643.
19. Kuhn, E., Wu, J., Karl, J., Liao, H. et al., Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4, 1175-1186.
20. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 2009, 8, 1860-1877.
21. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr, Cooper, G. R. et al., Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 1996, 42, 1676-1682.
22. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W. et al., Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6940-6945.
23. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
24. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B. et al., Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 2004, 3, 235-244.
25. Whiteaker, J. R., Zhao, L., Zhang, H. Y., Feng, L. C. et al., Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal. Biochem. 2007, 362, 44-54.
26. Whiteaker, J. R., Zhao, L., Anderson, L., Paulovich, A. G., An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 2010, 9, 184-196.
27. Hoofnagle, A. N., Becker, J. O., Wener, M. H., Heinecke, J. W., Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin. Chem. 2008, 54, 1796-1804.
28. Kuhn, E., Addona, T., Keshishian, H., Burgess, M. et al., Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 2009, 55, 1108-1117.
29. Neubert, H., Gale, J., Muirhead, D., Online high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS: assay development for total salivary pepsin/pepsinogen. Clin. Chem. 2010, 56, 1413-1423.
30. Whiteaker, J. R., Zhang, H., Zhao, L., Wang, P. et al., Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007, 6, 3962-3975.
31. Berna, M., Schmalz, C., Duffin, K., Mitchell, P. et al., Online immunoaffinity liquid chromatography/tandem mass spectrometry determination of a type II collagen peptide biomarker in rat urine: Investigation of the impact of collision-induced dissociation fluctuation on peptide quantitation. Anal. Biochem. 2006, 356, 235-243.
32. Gobom, J., Kraeuter, K. O., Persson, R., Steen, H. et al., Detection and quantification of neurotensin in human brain tissue by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 2000, 72, 3320-3326.
33. Ukena, K., Iwakoshi, E., Minakata, H., Tsutsui, K., A novel rat hypothalamic RFamide-related peptide identified by immunoaffinity chromatography and mass spectrometry. FEBS Lett. 2002, 512, 255-258.
34. Rush, J., Moritz, A., Lee, K. A., Guo, A. et al., Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 2005, 23, 94-101.
35. Jiang, J., Parker, C. E., Hoadley, K. A., Perou, C. M. et al., Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics Clin. Appl. 2007, 1, 1651-1659.
36. Hoeppe, S., Schreiber, T. D., Planatscher, H., Zell, A. et al., Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification. Mol. Cell. Proteomics 2011, 10, M110.002857.
37. Domanski, D., Murphy, L. C., Borchers, C. H., Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal. Chem. 2010, 82, 5610-5620.
38. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J. et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10, 515-527.
39. Whiteaker, J. R., Zhao, L., Abbatiello, S. E., Burgess, M. et al., Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 2011, 10, M110.005645.
40. Schoenherr, R. M., Zhao, L., Whiteaker, J. R., Feng, L. C. et al., Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry. J. Immunol. Methods 2010, 353, 49-61.
41. Razavi, M., Pope, M. E., Soste, M. V., Eyford, B. A. et al., MALDI immunoscreening (MiSCREEN): a method for selection of anti-peptide monoclonal antibodies for use in immunoproteomics. J. Immunol. Methods 2011, 364, 50-64.
42. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
43. MacLean, B., Tomazela, D. M., Abbatiello, S. E., Zhang, S. et al., Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. Anal. Chem. 2010, 82, 10116-10124.
44. Campbell, J., Rezai, T., Prakash, A., Krastins, B. et al., Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics 2011, 11, 1148-1152.
45. Harvey, J. M., Clark, G. M., Osborne, C. K., Allred, D. C., Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17, 1474-1481.
46. Zang, L., Palmer Toy, D., Hancock, W. S. et al., Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. J. Proteome Res. 2004, 3, 604-612.
47. Baker, H., Patel, V., Molinolo, A. A., Shillitoe, E. J. et al., Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol. 2005, 41, 183-199.
48. Moeder, C. B., Giltnane, J. M., Harigopal, M., Molinaro, A. et al., Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J. Clin. Oncol. 2007, 25, 5418-5425.
49. Cronin, M., Sangli, C., Liu, M. L., Pho, M. et al., Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 2007, 53, 1084-1091.
50. Sauer, G., Schneiderhan-Marra, N., Kazmaier, C., Hutzel, K. et al., Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin. Cancer Res. 2008, 14, 3345-3353.
51. Schneiderhan-Marra, N., Sauer, G., Kazmaier, C., Hsu, H. Y. et al., Multiplexed immunoassays for the analysis of breast cancer biopsies. Anal. Bioanal. Chem. 2010, 397, 3329-3338.